Lung cancer survival rate prolonged with AstraZeneca’s Imfinzi

AstraZeneca’s Imfinzi, which enables the immune system to detect and attack certain cancer cells, when combined with chemotherapy has been shown to lengthen patient’s lives with an aggressive type of lung cancer by nearly to three months.

Patients in the Phase III Caspian trial treated with Imfinzi and chemotherapy resulted in a median 13-month survival and the reference group on chemotherapy only lived a median 10.3 months.

Click here to read the entire article.